Regulatory Strategy & Pathway Planning
Every FDA programme begins with the right strategy. We assess your compound or device, your clinical data and your commercial objectives to define the most efficient approval pathway — NDA, ANDA, 505(b)(2), BLA, IND or device premarket submission.
- Application type selection (NDA, ANDA, 505(b)(2), BLA)
- Target product profile development
- Pre-clinical and clinical study design guidance
- Regulatory gap analysis and risk mapping
- Multi-jurisdictional pathway planning (FDA + TGA/EMA)


